American Pharmacy News
  • State Issues
  • Regulatory
  • Federal Issues
  • Industry
  • Innovation
  • Directory
  • State Issues
  • Regulatory
  • Federal Issues
  • Industry
  • Innovation
  • Directory
  • Home
  • »
  • 2016
  • »
  • October

Ajanta releases Omeprazole and Sodium Bicarbonate Powder for Oral Suspension in U.S.

American Pharmacy News Reports | Oct 7, 2016
Ajanta Pharma USA has made Omeprazole and Sodium Bicarbonate Powder for Oral Suspension available in the United States.

Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of Ajanta’s expanding profile of products that the company has developed specifically for the U.S. market. Ajanta has 26 Abbreviated New Drug Applications (ANDAs) submitted to the U.S. Food and Drug Administration.

Of these ANDAs, 14 are on final approval, two have tentative approval and 10 remain under review.
More News

Jonathan Levitt, Founding Partner, Frier Levitt

Industry Frier Levitt partner on CVS Health 340B lawsuits: CVS diverted funds ‘designated to help safety-net hospitals care for the most vulnerable’ May 28, 2026

Brian Hanna, Executive Director of the Cannabis Regulatory Agency

State Issues Cannabis Regulatory Agency seeks new members for diversity, equity, and inclusion workgroup May 26, 2026

Sally Pipes, President & CEO of Pacific Research Institute

Innovation Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B' May 25, 2026

B. Douglas Hoey CEO

State Issues Tennessee enacts law banning pharmacy benefit managers from owning pharmacies May 22, 2026

Anne McDonald Pritchett, PhD, founder of Pritchett Policy Associates

Industry Pritchett Policy Associates founder Pritchett on biosimilar access: 'PBMs are the problem not patents' May 22, 2026

Ryan Long, Director of Congressional Relations & Senior Research Fellow at Paragon Health Institute

Federal Issues Paragon Health Institute senior fellow calls for 340B reform: Primary recipients of 340B are ‘wealthier larger hospital systems’ May 22, 2026

Trending

Sally Pipes, President & CEO of Pacific Research Institute

Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B'

West Cuthbert, Senior Fellow, American Resolve Action

American Resolve Action Senior Fellow on 340B reform: Oversight 'could prevent billions of dollars in annual waste, fraud, and abuse'

Jonathan Levitt, Founding Partner, Frier Levitt

Frier Levitt partner on CVS Health 340B lawsuits: CVS diverted funds ‘designated to help safety-net hospitals care for the most vulnerable’

B. Douglas Hoey CEO

NCPA supports pharmacy bills being marked up in House committees

Brian Hanna, Executive Director of the Cannabis Regulatory Agency

Cannabis Regulatory Agency seeks new members for diversity, equity, and inclusion workgroup

Copyright © 2026 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up